SLC5A2 and heart failure: The meta-analysis of the DELIVER and EMPEROR-Preserved trials showed that the SGLT2 inhibitors dapagliflozin and empagliflozin similarly and robustly reduced cardiovascular death or hospitalization for heart failure among patients with mildly reduced and preserved ejection fraction compared with placebo.